Eosinophilic Pneumonia Due to Sulphasalazine Use

S. Sökücü (Istanbul, Turkey), C. öZdemir (Istanbul, Turkey), ö. Kahya (Istanbul, Turkey), S. Tural öNüR (Istanbul, Turkey)

Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs)
Disease area: Interstitial lung diseases

Congress or journal article abstract

Abstract

Sulfasalazine is a compound of 5-aminosalicylic acid and sulfapyridine joined by an azo bond. There are only case reports in the literature about pulmonary toxicity caused by this drug. A 23-year old man diagnosed as ulcerative colitis 3 months ago admitted to our hospital  with a 1 month history of fever, cough, dyspnoea. He didn't respond to antibiotics. He was a nonsmoker and had been on sulfazalazine  and mesalazine treatment for 8 weeks.  All of his medications were held on admission. He had fever (38.6 °C) with respiratory rate of 20/min with normal oxygen saturations in room air Physical examination revealed crepitation over right lung on auscultation. Chest radiograph showed multilobar pulmonary infiltrates dominated right lung peripherally . He has peripheral eosinophilia. For differential diagnosis, an autoimmune screen, Ig E level and parasite search in his feces was negative. Sputum culture was negative for pathogenic bacteria and acid-fast bacilli. HRCT revealed patchy consolidations at all zones of the right lung and upper zone of left lung, peribronchial and interlobuler septal thickenings, ground glass opasities. No endobronchial pathology was detected.  Bronchoalveolar lavage done from medial segment of right middle lobe was negative for viral, tuberculous and fungal infections. The differential cell count showed 20% eosinophils. After withdrawal of sulfazalazine, pulmonary infiltrates started to regress in the control chest radiograph  but respiratory symptoms were not resolved completely so oral prednisone treatment was started. 2 weeks later, his chest radiograph was dramatically improved with near complete resolution of the pulmonary infiltrates.The patient is in our follow up for 6 months without any symptoms.

  



Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Sökücü (Istanbul, Turkey), C. öZdemir (Istanbul, Turkey), ö. Kahya (Istanbul, Turkey), S. Tural öNüR (Istanbul, Turkey). Eosinophilic Pneumonia Due to Sulphasalazine Use. 3026

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
DRESS to Impress: A Case of Eosinophilic Bronchiectasis with Systemic Sequelae
Source: Virtual Congress 2021 – CCC Paediatric respiratory diseases
Year: 2021


Eosinophilic pneumonias
Source: Eur Respir Monogr 2022; 95: 141-152
Year: 2022


Immunogenicity of Mepolizumab in Patients with Severe Eosinophilic Asthma: Experience from the Clinical Development Program
Source: International Congress 2018 – Novel immunology-based therapies in asthma and COPD
Year: 2018



Misdiagnosis of Asthma May Delay the Post Infectious Bronchiolitis Obliterans Diagnosis
Source: International Congress 2019 – New insights into childhood infections: from viral bronchiolitis to bronchiolitis obliterans
Year: 2019


Community-Acquired Pneumonia with Evolving Cavitation and Peripheral Eosinophilia
Source: International Congress 2018 – CC8 Non-resolving pneumonia
Year: 2018


Assessment of Treatment Response in Granulomatous Lymphocytic Interstitial Lung Disease (GLILD)
Source: International Congress 2019 – The changing face of rare diffuse parenchymal lung diseases: recent advances in pathogenesis, clinical manifestations and treatment
Year: 2019


Exacerbations and pneumonia in bronchiectasis: Clinical and microbiological characterization
Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook
Year: 2015

Modes of Disease Progression in Different Forms of Interstitial Lung Disease with Usual Interstitial Pneumonia Histology in Patients with Idiopathic and Non-idiopathic Etiologies - A Single Center Experience
Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside
Year: 2019

Effect of Antifibrotic Therapies in Patients with Interstitial Pneumonia with Autoimmune Features
Source: Virtual Congress 2020 – Non-idiopathic pulmonary fibrosis interstitial lung diseases: mechanisms, diagnosis and treatment
Year: 2020


Methylprednisolone pulse therapy in Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis
Year: 2020


Pneumonia
Source: Eur Respir Monogr 2018; 79: 87-101
Year: 2018


Pneumonia
Source: ISSN=ISSN 1810-6838, ISBN=, page=195
Year: 2007

Pneumonia in women-smokers
Source: Annual Congress 2007 - Smoking and the lung
Year: 2007


Eosinophilic asthma
Source: Eur Respir Monogr 2022; 95: 73-99
Year: 2022


Amphetamine induced eosinophilic pneumonia: A case report
Source: International Congress 2014 – ILDs 6
Year: 2014

What Can Be Expected From Pathology Assessment? Or: Is Severe Asthma Still an Eosinophilic Disease?
Source: Research Seminar 2007 - Severe Asthma
Year: 2007


Progressive Phenotype in Chronic Hypersensitivity Pneumonitis
Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis
Year: 2020


Bacterial Contamination of Home Nebulizers in Children with Cystic Fibrosis and Clinical Implication on the Number of Pulmonary Exacerbations
Source: International Congress 2019 – Infection and inflammation in cystic fibrosis
Year: 2019


Eosinophilic pneumonia associated with pirfenidone therapy
Source: Eur Respir J 2016; 48: 1240-1242
Year: 2016


Eosinophilic COPD
Source: Eur Respir Monogr 2022; 95: 100-118
Year: 2022